<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02025205</url>
  </required_header>
  <id_info>
    <org_study_id>630-0014</org_study_id>
    <nct_id>NCT02025205</nct_id>
  </id_info>
  <brief_title>Improving Patient Outcomes by Selective Implantation of the Zephyr EBV - Study</brief_title>
  <acronym>IMPACT</acronym>
  <official_title>A Multicentre, Prospective, Randomized, Controlled, One-way Crossover Investigation of Endobronchial Valve (EBV) Therapy vs. Standard of Care (SoC) in Homogeneous Emphysema</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pulmonx International Sàrl</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pulmonx, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this prospective, randomized, controlled, one-way crossover study is to assess and
      compare the efficacy of the Zephyr endobronchial valves vs. Standard of Care (SoC) in
      patients suffering from COPD with Homogeneous Emphysema. Patients will be followed up for 12
      months after randomization. Patients in the SoC arm will crossover to the EBV treatment arm
      after the 6-month visit and will be followed up for 6 additional months.The primary objective
      is the variation of FEV1 between baseline and 3-month follow-up visit. The secondary
      objectives will evaluate quality of life, exercise capacity, dyspnea (including BODE index)
      changes, target lobe volume reduction, as well as safety outcomes.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">August 2014</start_date>
  <completion_date type="Actual">March 15, 2017</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage change in Forced Expiratory Volume in 1 s (FEV1)</measure>
    <time_frame>At baseline and after 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Quality of life (FEV1, SGRQ, CAT, EQ-5D)</measure>
    <time_frame>At baseline and after 3, 6 and 12 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Exercise Capacity (6-MWT)</measure>
    <time_frame>At baseline and after 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Dyspnea (mMRC)</measure>
    <time_frame>At baseline and after 3 and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events and Serious Adverse Events</measure>
    <time_frame>At each visits</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">93</enrollment>
  <condition>COPD Patients With Homogeneous Emphysema</condition>
  <condition>Endoscopic Lung Volume Reduction With Endobronchial Valve</condition>
  <arm_group>
    <arm_group_label>ELVR with Endobronchial Valves</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Patients will receive optimal drug therapy and medical management according to clinical practice.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Endobronchial Valve</intervention_name>
    <description>Endoscopic Lung Volume Reduction with Zephyr Endobronchial Valve</description>
    <arm_group_label>ELVR with Endobronchial Valves</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homogeneous emphysema

          -  15% &lt; or = FEV1 &lt; or = 45% predicted

          -  TLC &gt; 100% predicted

          -  RV &gt; or = 200% predicted

          -  6-MWT &gt; or = 150 m

          -  Non-smoker &gt; 8 weeks prior to study entry

          -  Absence of Collateral Ventilation in the target lobe

        Exclusion Criteria:

          -  Active pulmonary infection

          -  More than 3 exacerbations with hospitalizations over the past 12 months

          -  Pulmonary hypertension (sPAP &gt; 45 mmHg)

          -  MI or other relevant CV events in the past 6 months

          -  Alpha-1 antitrypsin deficiency

          -  Bronchiectasis

          -  Prior LVR or LVRS procedure

          -  &gt; 20% difference in perfusion between right and left lung

          -  Hypercapnia (paCO2 &gt; 55 mmHg

          -  Asthma

          -  Use of more than 25 mg/day prednisolone or equivalent

          -  Severe bullous emphysema

          -  Systemic or malignant disease with high death probability within 12 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Arschang Valipour, MD, PhD, FCCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ludwig-Boltzmann-Institute for COPD and Respiratory Epidemiology Otto-Wagner-Spital 1140 Wien / Austria</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ludwig-Boltzmann-Institut für COPD und Pneumologische Epidemiologie</name>
      <address>
        <city>Vienna</city>
        <zip>1140</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Charité Campus Virchow-Klinikum</name>
      <address>
        <city>Berlin</city>
        <zip>13353</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ruhrlandklinik, Westdeutsches Lungenzentrum</name>
      <address>
        <city>Essen</city>
        <zip>45239</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenabteilung Thoraxzentrum Hamburg</name>
      <address>
        <city>Hamburg</city>
        <zip>21075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thoraxklinik am Universitäts klinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69126</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lungenklinik Hemer</name>
      <address>
        <city>Hemer</city>
        <zip>58675</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Klinikum Nürnberg Nord</name>
      <address>
        <city>Nürnberg</city>
        <zip>90419</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of pulmonary dieases, University Medical Center</name>
      <address>
        <city>Groningen</city>
        <zip>9700RB</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Austria</country>
    <country>Germany</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 21, 2013</study_first_submitted>
  <study_first_submitted_qc>December 27, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 31, 2013</study_first_posted>
  <last_update_submitted>October 9, 2017</last_update_submitted>
  <last_update_submitted_qc>October 9, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Emphysema</mesh_term>
    <mesh_term>Pulmonary Emphysema</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

